Reunion Neuroscience, a New Jersey biotech that spun out from the ill-fated ketamine clinic chain Field Trip Health two years ago, has announced a $103m Series A financing co-led by MPM BioImpact and Novo Holdings, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo. The lofty Series A is reminiscent of similarly large…
